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Summary 26 
Background: Severe imported Plasmodium falciparum malaria is a potentially life-threatening 27 
disease with a reported mortality rate of 4-10% when patients are admitted to the Intensive Care 28 
Unit. 29 
Methods:  To retrospectively review the clinical aspects, the value of severity predictive scores and 30 
the management of patients with severe P. falciparum malaria admitted to an ICU in Milano, Italy 31 
between January 2010  and December 2015 32 
Results : Twelve patients were included: seven were male and five female with a median age of 43 33 
years. All were initially treated with intravenous quinine. Median parasitemia upon admission was 34 
14.5% (range 1-20%). At the time of ICU admission, 3 patients (25 %) had 5 or more World Health 35 
Organization criteria for severe malaria while another 6 of them developed one or more of the latter 36 
during their stay in ICU. Five required mechanical ventilation because of respiratory failure due to 37 
ARDS. Four patients required renal replacement therapy. Three patients underwent blood exchange 38 
transfusion. All patients survived  39 
Conclusions: Our retrospective evaluation of adults patients admitted to the ICU with severe 40 
imported P. falciparum malaria demonstrated a favourable outcome. Severity predictive scores 41 
currently in use probably overestimate the risk of malaria mortality in patients treated in health care 42 
systems of high income countries. 43 
44 
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1. Introduction 45 
 46 
Although declining worldwide, malaria was responsible in 2015 of 214 million clinically apparent 47 
cases and 438.000 associated deaths. A disproportionate majority (90%) of cases still occurred in 48 
sub-Saharan Africa  with death (67%) observed especially among under-five years children [1].  49 
In 2012 , 5.161 cases of imported malaria were recorded in the European Union          (incidence 50 
rate: 0.88 cases per 100.000)  with the United Kingdom (UK) and France contributing to the 51 
majority of cases [2]. Of the five species responsible of naturally transmitted infections in humans, 52 
Plasmodium falciparum is recognized as causing most of imported malaria cases in Europe and 53 
because infection with this micoorganism may rapidly evolve to a life-threatening multi-system 54 
organ disease it is associated with almost all cases which require admission to the intensive care 55 
unit (ICU) [3-5]. Analysis of large database from France and UK showed that  case-fatality rate 56 
associated with P. falciparum malaria was in the order of 0.4 % and    0.73 %, respectively [5,6]. 57 
However, ICU mortality in severe cases of P. falciparum infection is reported to be in the average 58 
of 5 to 10% [3,8,9]. Furthermore, a study of all malaria cases reported to the Centers for Diseases 59 
Control in the USA from 1985 to 2011 showed that P. falciparum was ten times as likely to cause 60 
death when compared with P. vivax, with a case-fatality rate of 0.9% [10]. 61 
In Western countries the risk of severe P. falciparum malaria and death was shown to be  associated 62 
with several factors such as initial misdiagnosis [11,12], patient delay to seek medical attention, the 63 
time required to obtain a diagnosis of malaria and delays in treatment inception and appropriateness 64 
[13]. 65 
The present paper aims to review the clinical aspects of, and the management strategies used in, 66 
patients with severe Plasmodium falciparum malaria admitted to the intensive care unit (ICU) of a 67 
University hospital in Milano, Italy during a 6-year period.  68 
 69 
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2. Patients and methods 71 
The Luigi Sacco Hospital (LSH) in Milano is a 550-bed Academic hospital that serves as a referral 72 
centre for patients with imported tropical diseases, including malaria. It has 2 infectious disease 73 
units with 76 inpatient beds and an 8-bed multidisciplinary ICU. 74 
The records of all patients with severe P. falciparum malaria admitted to the ICU of LSH from 75 
January, 2010 to December, 2015 were retrospectively reviewed. 76 
Severe and complicated malaria was defined according to the 2000 World Health Organization 77 
criteria [14]. In brief, in the presence of asexual forms of P. falciparum in the blood, the presence of 78 
one of more of the following features defines severe malaria: 1) impaired consciousness (Glasgow 79 
Coma scale < 11); 2) pulmonary oedema or adult respiratory distress syndrome; 3) circulatory 80 
collapse (systolic blood pressure< 80 mmHg despite adequate volume repletion); 4) severe anaemia 81 
with a haemoglobin level < 7 g/L (in adult patients); 5) hypoglicaemia with a blood glucose level < 82 
40 mg/dL; 6) abnormal bleeding and/or disseminated intravascular coagulation (DIC); 7) renal 83 
failure with a serum creatinine concentration > 3 mg/dl and/or a 24-hour urine output of < 400 mL 84 
despite adequate re-hydration; 8) acidosis (blood pH < 7.35 or a serum bicarbonate level < 15 85 
mmol/L or hyperlactataemia (plasma lactate level > 5 mmol/L); 9) jaundice or total bilirubin level > 86 
3 mg/dL; 10) hyper-parasitemia (parasite count > 5%); 11) repeated generalized seizures; 12) 87 
hemoglobinuria. 88 
Acute lung injury was defined as the acute onset of bilateral pulmonary infiltrates on chest X-ray or 89 
CT scan with a PaO2/FIO2 < 300 mmHg, regardless of positive end-expiratory pressure (PEEP) 90 
levels. Patients with acute lung injury and a PaO2/FIO2 below 200 mmHg were classified as having 91 
ARDS [15]. 92 
Parasite counts were calculated as the percentage of parasitized red blood cells (RBC) observed by 93 
direct microscopy in a thin blood film. The treating physician ordered serial peripheral blood film 94 
examinations during the clinical management of patients with a frequency that was at his discretion 95 
and until malaria parasites could not be observed any longer.  96 
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The decision to employ red blood cell exchange was taken by the treating physician, in conjunction 97 
with specialists in transfusion medicine.  98 
Three prognostic malaria scores were calculated for each patient admitted in the ICU, namely the 99 
Malaria Score for Adults (MSA), the Coma Acidosis Malaria (CAM) scoreand the Malaria Severity 100 
Score. Malaria Score for Adults (MSA) is obtained by the sum of the following conditions each 101 
assigned a pre-definite point and ranges from 0 to 10: 1 x (severe anemia [haemoglobin level < 102 
5 g/dL]) + 2 (acute renal failure [creatinine level>3 mg/dL])+ 3 (respiratory distress, 103 
requiring mechanical ventilation)+ 4 x (cerebral malaria, [GCS < 11V), in which each variable 104 
was scored as 0 or 1 [16]. Coma Acidosis Malaria (CAM) score is calculated as the base deficit 105 
score (0-2) as follows : base deficit  < 2 =0; 2 to < 10= 1; > 1=2 plus the Glasgow Coma Score 106 
(GCS; 0-2): 15=0; > 10 to 14=1; < 10=2.  Respiratory rate-based CAM score (0-4) is calculated as 107 
the respiratory score (0-2) as follows : respiratory rate < 20=0; 20 to <40=1; > 40=2 plus the GCS 108 
score (0-2) as previously described [17]. 109 
The Malaria Severity Score that defines dysfunction in 7 organ systems with 3 levels of severity and 110 
assigning 1, 3 and 5 points to level I, II and III severity of organ dysfunction respectively. The score 111 
ranges from 0 to 21 with risk of mortality calculated for each score [18].  112 
Clinical severity at ICU admission was also assessed using the  APACHE II score [19], SAPS II 113 
score [20] and SOFA score [21].  114 
 115 
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 117 
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3. Results 121 
Between January 2010, and December 2015, 177 adult patients with 180 diagnosis of malaria were 122 
cared for at the LSH in Milano (data not shown). Except for 30 P. vivax, seven P. ovale , four P. 123 
malariae and three mixed P. falciparum –P. vivax infections, all other patients (136, 75.5%) 124 
suffered from P. falciparum malaria.  125 
Twelve patients (6.6%), with a median age of  43 years (range 28-59 years) were admitted to our 126 
ICU due to the presence of clinical and laboratory features of severe P. falciparum malaria 127 
according to WHO criteria (Table 1). Seven patients were male and five female ; except for 4 128 
African patients all were Italians. Upon admission to the ICU, 3 patients (25 %) had 5 or more 129 
WHO criteria for severe malaria while during the ICU stay 6 additional patients developed one or 130 
more WHO criteria for severe malaria. 131 
Five patients were admitted directly to the ICU from our Emergency Department (ED), four were 132 
transferred from the ED of neighbouring hospitals, two were transferred from the infectious 133 
diseases and internal medicine departments of our Hospital and one was airlifted from Africa and 134 
directly hospitalized to our ICU upon arrival in Italy.  135 
All individuals had acquired the infection in sub-Saharan countries of West or Central Africa: 3 136 
from Senegal, 2 from Nigeria, 2 from Cameroon, 2 from Ivory Coast and 1  each from Congo, 137 
Sierra Leone and Uganda). Eleven patients were returning to Italy while one was visiting our 138 
country for the first time. The main clinical and epidemiological characteristics of each patient are 139 
summarized in Table 1. Of note, none of them had taken antimalarial chemoprophylaxis. In all 140 
patients who were diagnosed with malaria while in Italy (n=11)  symptoms appeared within a 141 
median of 10 days (range 8-14 days) from arrival. The median time between symptoms onset and 142 
the time when patients first sought medical attention was 3.5 days (range 1-13 days) and 143 
corresponded in all cases but three (patient # 10 #11 and #12), with the time when the diagnosis of 144 
malaria was made. The 3 patients in whom the diagnosis of malaria was initially overlooked were 145 
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either discharged by the ED without ruling-out a diagnosis of this infection or, in one case, were 146 
hospitalized  with an erroneous diagnosis (acute pyelonephritis).  147 
The median delay with which the diagnosis of malaria was made in these patients was 8 days (range 148 
3-9 days). For all other individuals who were correctly diagnosed at the first observation, the 149 
median time from presentation  to the ED and the parasitological diagnosis of malaria was 2.7 hours 150 
(range 1,16-9,30 hours) while the median time elapsing from the parasitological diagnosis of 151 
malaria and the first dose of quinine administered was 2 hours (range 1,20-4,30 hours). Globally, 152 
the median time from presentation to the hospital and the beginning of antimalarial therapy was 153 
4,45 hours (range 2,36-14 hours). 154 
The median length of hospitalization was 11,5 days (range 8-43 days) and the median time spent in 155 
the ICU was 5 days (range 1-21 days). The median number of WHO criteria for severe malaria 156 
observed at the time of admission was 3 (range 1-8) and during stay in ICU 2.5 (range 1-4) 157 
additional criteria of severe malaria developed. Jaundice was present in ten patients (83.3%), shock 158 
in four (33,3%). Specifically, while in ICU, five patients developed ARDS a median of 3 days after 159 
admission and in additional two shock ensued. Impaired consciousness was present at the time of 160 
hospitalization in 4 patients (33.3%). Acute renal failure with oligo-anuria was observed in 4 161 
patients (33.3%) and required in all cases renal replacement treatment. 162 
The two patients with low levels of parasitaemia (#6 and #10) were notable in one case for the 163 
development of  severe anemia (Hb 6.9 g/dL) and highly elevated levels of transaminases (AST 676 164 
U/L, ALT 646 U/L), LDH (713 U/L) and bilirubin (13,4 mg/dL) and in the other for the severe 165 
renal failure and the development of ARDS requiring mechanical ventilation on the third day of 166 
ICU hospitalization.  167 
Thrombocytopenia was the haematologic alteration observed in all patients (median value 168 
29,000/µL, range 7000-68.000/µL); anemia was present in 10 patients (median Hb 8.4 g/dL, range 169 
6.5-14.5 g/dL) in 10 patients and was classified as severe in three patients. Other relevant laboratory 170 
parameters (Table 2) were: hyponatriemia, present in 11 patients with a median value of 131 171 
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mmol/L (range 122-134 mmol/L);  hypoalbuminaemia, detected in all patients (10) for whom this 172 
data was available (median 2200 mg/L, range 1400-2600 mg/dL) and hyperlactataemia (> 5 173 
mmol/L) observed in two patients. 174 
Four patients received inotropic drugs and five mechanical ventilation (median 7 days, range 3-14 175 
days). Nine patients received blood transfusions although only two fulfilled strict criteria for severe 176 
anemia. Two patients underwent blood exchange transfusion with, respectively, 1500 and 3000 mL 177 
of red blood cells and fresh frozen plasma and one patient underwent erythrocytapheresis. Two 178 
patients received platelet transfusion. 179 
3.1 Kinetic of parasite clearance times 180 
Sixty-eight examinations of peripheral blood were performed (a mean of 5.7 determinations per 181 
patient). High parasitaemia (≥ 5%) was observed at baseline in ten patients (83,3%) with a median 182 
value on the first day of 14.5 % (range 1,0-20 %). Patient # 2 after the initiation of antimalarial 183 
treatment had a marked increase of parasitaemia (27%) that prompted the start of blood exchange 184 
transfusion with a rapid decrease (1%) within the next 12 hours. The other two patients (# 8 and #9) 185 
who underwent erythrocytapheresis or blood exchange transfusion had a drop of parasitaemia from 186 
the baseline level (20 and 17%) to 0,5% within 24 hours. 187 
The median time required to achieve a negative blood parasitemia in all 12 patients was 77 hours 188 
(range 54-144 hours).  189 
 190 
3.2 Scores of severity 191 
In table 2 are shown the different scores calculated upon admission in the ICU for all patients 192 
(patient #4 had 2 admission in the ICU). Patient # 5,8,9 and 10 had the highest scores using the 193 
APACHE II, SAPS II and SOFA scores with the corresponding highest predicted mortality.  The 194 
same patients were identified with the highest scores by MSA, MSS and CAM with the exception 195 
of patient #10 who had lower scores with MSS and CAM. Also for patient # some discrepancies 196 
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with the application of different scores were observed. It seems that all scores were able to identify 197 
patients with very severe malaria but they overestimate mortality prediction. 198 
3.3 Treatment 199 
All patients admitted to the ICU received intravenous quinine dihydrochloride treatment with a 200 
loading dose of 20 mg/kg body weight administered over 4 h followed by 10 mg/kg body weight 201 
every 8 h until they were able to take oral medication. Six patients completed oral antimalarial 202 
therapy either with quinine (n=4 patients) or with dihydroartemisinin-piperaquine (n=2 patients). At 203 
discretion of the caring physician, nine patients also received intravenous or oral doxycycline at a 204 
dose of 100 mg every 12 hours for seven days. 205 
All patients survived and at the time of discharge all complications related to severe malaria 206 
resolved except for mild renal insufficiency in two individuals and persistent renal failure in one 207 
patients who is, at the time of writing, still under  renal replacement therapy. 208 
 209 
4. Discussion 210 
In this retrospective study, we describe 12 consecutive patients with severe P. falciparum malaria 211 
(in one case associated with P. vivax) who were admitted to our ICU. Altogether,  they represent 212 
6.6% of all cases of P. falciparum malaria observed at LSH who were admitted to the ICU during a 213 
6-year period. Consistent with a recent review of the literature regarding adults patients with P. 214 
falciparum malaria requiring intensive care, all our patients acquired the infection in sub-Saharan 215 
Africa and none of them had taken chemoprophylaxis [3]. The latter issue is particular worrisome 216 
because among these patients three had long-term working experience in malaria-endemic areas and 217 
another three volunteers engaged in humanitarian aid programmes with multiple and prolonged 218 
period of stay in Africa, both conditions that should have raised their awareness of the risk of 219 
contracting malaria.  220 
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The median time from patient symptom onset to healthcare access was in our experience 3.5 days 221 
that is exactly the same interval reported in the two largest single centre studies of imported P. 222 
falciparum malaria  requiring ICU admission [22,23].  223 
In a study conducted in the USA regarding malaria deaths among travellers, failure to take 224 
chemoprophylaxis or to seek medical attention promptly, together with medical errors, were 225 
considered the variables associated with 85% of preventable deaths [13]. In fact, three patients who 226 
developed complications of severe malaria were initially misdiagnosed at the ED .It is tempting to 227 
speculate whether a correct diagnosis would have avoided these patients both the ICU admission 228 
and the subsequent complications.  229 
Although our study was retrospective, we had the opportunity to evaluate two key elements in the 230 
management of patients with severe malaria, namely the interval of time from initial evaluation at 231 
the ED to the diagnosis of malaria and the time elapsed between diagnosis of the disease and the 232 
beginning of antimalarial treatment with intravenous quinine. The median values for these intervals 233 
were, respectively, 2.7 and 2 hours. It is well known from experience in other severe infections that 234 
a delay in starting the appropriate antimicrobial therapy is associated with a worse outcome but we 235 
are not aware of any study of severe malaria where the interval time from diagnosis to beginning of 236 
specific therapy was associated with patient outcome. We wonder whether the relatively short 237 
intervals of time recorded in this study may in part explain the favourable outcome observed in our 238 
patients. Although we believe that our results are indicative of a high level of suspicion regarding 239 
malaria infection among physicians in our hospital, we acknowledge that there is still room for 240 
improvement in both temporal variables.  241 
Even when high quality healthcare is available, the mortality rate in adults associated with imported 242 
severe P. falciparum malaria ranges from 5% to 10.5 % [8,23]. In a prospective multicenter study 243 
conducted in France from 2007 to 2010, Bruneel et al. showed a trend toward a lower mortality in 244 
comparison with their previous study (from 10.5% to 5.2%) but this figure is still somewhat 245 
elevated. By contrast, in the TropNet severe malaria study the overall mortality rate was 1.6% with 246 
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no significant differences among patients treated with artesunate (1.6%) and quinine (2.2%) [24,25]. 247 
However, the results of two large comparative trials conducted in Asia and Africa (AQUAMAT and 248 
SEQUAMAT), showed that parenteral artesunate, reduced mortality among adults and children 249 
when compared with quinine, and  for this reason the former is now recommended as the drug of 250 
choice for the treatment of severe P. falciparum malaria [26,27]. Nevertheless, in non-endemic 251 
areas it is still controversial whether intravenous artesunate, despite being associated with faster 252 
parasite clearance rates and more rapid resolution of fever and shorter ICU stays, is capable to 253 
further reduce malaria mortality [28]. In this regard, three recently published studies from Belgium 254 
and the Netherlands, USA and France report mortality rates among patients with severe malaria 255 
treated with intravenous artesunate of, respectively, 3.6 %, 6.9% and 4.9% [29-31]. However, we 256 
agree with the statements by Roussel et al. who recently reviewed the role of artesunate in the 257 
treatment of severe malaria in travellers [32]. In Europe, the drug need to be submitted to full good 258 
manufacturing practice (GMP) qualification followed by a rapid approval  by European Medicines 259 
Agency (EMA) in order to be available as first choice therapy of severe malaria.  260 
Red blood cell exchange an adjunctive treatment employed to rapidly clear peripheral blood 261 
parasitemia in severe malaria has not yet been shown, to our knowledge, to confer an improvement 262 
in patient survival. Indeed, this intervention was recently shown not to provide faster parasite 263 
clearance rates in patients currently treated with intravenous artesunate [33-35]. We used RBC 264 
exchange in three patients with very high parasitemia but despite rapidly achieving fast reduction 265 
we cannot made any conclusion. 266 
Severe P. falciparum malaria is defined by the World Health Organization (WHO) criteria which 267 
were formulated with the objective to identify those patients who would benefit from intensive 268 
monitoring and parenteral antimalarial treatment. However, in this regard,  not all criteria display 269 
the same capacity to identify patients with a poor prognosis as well as patients who will benefit for 270 
immediate admission to the intensive care unit. In the 400-patient cohort study conducted in France 271 
by Bruneel et al., three variables present at ICU admission independently predicted death: older 272 
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age, coma and high parasitemia [8]. Identifying patients with severe imported malaria at high-risk 273 
of death in ICU is of paramount importance.  274 
Three recently described  scoring systems- Coma Acidosis Malaria (CAM) score, Malaria Score in 275 
Adults (MSA) and Malaria Severity Score (MSS) were proposed in order to predict mortality risk of 276 
P. falciparum malaria in adults [16-18]. All these scores have been validated in studies conducted in 277 
South-East Asia [17] and India [16,18] where the standard of intensive care are probably not the 278 
same of Europe. The AUROC (area under the receiver operating characteristic curve) for the MSA 279 
score and CAM score for predicting death (applied to patients enrolled in the SEAQUAMAT) were 280 
0.75 and 0.81, respectively [17].However, the high positive predictive value of both scores, 95.8% 281 
for CAM (with a score of less than 2)  and 94.1% for MSA (with a cut-off of 5) were more 282 
predictive of survival than death. Marks et al. applied  the CAM and MSA score to 124 patients 283 
with severe P. falciparum malaria admitted to their ICU in London showing, in agreement with the 284 
above cited results, that these scores performed poorly in predicting mortality [23]. In another 285 
retrospective study conducted in Portugal among 59 patients with severe malaria admitted to the 286 
ICU, SAPS II and WHO score were the most sensitive in predicting death with an AUROC of 0.90 287 
and 0.91, respectively [36]. 288 
In our study, the application of CAM, MSA and MSS scores to a small series of patients with 289 
severe P. falciparum malaria admitted to the ICU showed that all of them had limited utility in 290 
estimating mortality risk being, at best, useful to assess the severity of malaria. In our opinion it is 291 
more useful the definition adopted by Bruneel et al. that among patients fulfilling the 2000 WHO 292 
criteria for severe malaria in adults identified two subgroups: those with very severe malaria (VSM) 293 
experiencing coma, shock, acidosis, hyperlactatemia (>5 mmol/L) or respiratory distress within the 294 
first 72 hours of the ICU and those with less severe malaria (LSV) (i.e., with none of the above 295 
criteria) [9]. In their valuable work the French authors showed that death occurred only in the 296 
subgroup of patients with VSM (mortality rate 10.5%) while all subjects with LSM survived [9].  297 
Interestingly, they noted that the best biomarkers associated with severity were plasma albumin and 298 
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soluble triggering receptor expressed on myeloid cells (sTREM-1) [9]. By contrast, in another study 299 
of imported malaria, te Witt et al. failed to demonstrate any discriminative power of TREM-1 levels 300 
measured upon hospital admission among patients with severe and uncomplicated P. falciparum 301 
malaria [37]. The same group showed that hyponatremia (with a value of < 131 mmol/L) was 302 
independently associated with severe falciparum malaria (OR 10.4) [38]. In our study, both 303 
hypoalbuminemia and hyponatremia were observed among patients with severe falciparum malaria 304 
and we believe that their widespread availability make them more attractive than other proposed 305 
biomarkers of malaria severity. Finally, we would like to highlight that 33% of patients admitted to 306 
our ICU with severe malaria were either VFR or migrants from highly endemic malaria areas . This 307 
observation adds to debate  over the duration of malaria semi-immunity of individuals from 308 
endemic areas and their resistance to severe malaria development [39-41]. Although it is generally 309 
acknowledged that individuals arriving from endemic areas tolerate higher levels of parasitaemia 310 
with fewer complications, one of our patient developed severe malaria despite a parasitaemia below 311 
the threshold considered at risk of severe malaria. We therefore would like to warn against 312 
considering recently arrived migrants from malaria-endemic areas as individuals not at-risk for 313 
severe malaria development and thus eligible for outpatient treatment of the disease [42]. 314 
4.1 Conclusions 315 
Our recent experience regarding the treatment of severe imported P. falciparum malaria in a small 316 
series of adult patients suggests that even those with more severe picture can have a favourable 317 
outcome if managed in an high specialized centre. We confirm that ARDS, one of the more feared 318 
complication tend to occur later respect other complications. Scores commonly used in the ICU and 319 
those developed for malaria seems able to recognize patients with more severe malaria but 320 
overestimate mortality risk. We believe that host presentation with shock or coma, high parasite 321 
biomass (detected by day 1 peripheral parasitaemia or plasma PfHRP-2 as recently suggested by 322 
Bruneel et al) together with lactic acidosis and hypoalbuminemia are the parameters associated with 323 
more severe malaria.324 
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Table 1- Epidemiologic, clinical and laboratory features of 12 patients with severe P. falciparum malaria admitted to the ICU 
Patient 
N° 
Sex, 
age 
Reason for 
travel 
Country of 
origin/ 
Country of 
disease 
acquisition 
Prophylaxis/ 
Therapy 
WHO criteria for 
severe malaria 
on ICU 
admission/ 
Criteria 
developing after 
ICU admission 
Time from 
symptom 
onset to 
health-care 
presentation 
(days) 
Time from 
initial 
evaluation to 
diagnosis 
(hours)/ Time 
from diagnosis 
to treatment 
(hours) 
Parasite 
level 
(initial) 
Blood 
transfusion 
(N° RBC 
Unit)/ 
Platelet 
transfusion 
(N° Unit) 
Inotropic 
drugs/ 
Mechanical 
ventilation 
(days) 
Exchan
ge 
transfus
ion (N° 
RBC 
unit/FF
P) 
CVVH
DF 
(days) 
Days 
in 
ICU/ 
Total 
hospita
l days 
1 M,33 VFR Nigeria/ 
Nigeria 
ND/Quinine 
iv+ 
doxycycline 
H/None 3 4,20/1,20 5% No/No No/No No No 4/8 
2 M,40 Work Italy/ 
Cameroon 
ND/Quinine 
iv+ 
doxycycline 
H, J/IC 6 3,30/2,00 5,8 % Yes (3)/No No/No Yes (4 / 
5) 
No 3/13 
3 F,59 Volunteer Italy/Ivory 
Coast 
ND/Quinine iv 
(2 d) then po+ 
doxycycline 
H/None 4 2,35/2,00 5,4% No/No No/No No No 1/9 
4 F,31 Recently 
immigrated 
Senegal/ 
Senegal 
ND/Quinine iv H,J,S,A,D, 
Hy/ARDS 
2 2,40/2,00 20 % Yes (4)/No Yes/Yes (4) No No 6 
(1+5)/
14 
5 M,47 Work Italy/Nigeri
a 
ND/Quinine iv 
(3 d) then po 
IC,S,RF,H,J,A 
/ARDS 
3 NA 15% Yes (4)/No Yes/Yes (7) No No 9/23 
6 M,45 Volunteer Italy/Congo ND/Quinine iv J, D ,He/SA 7 5,00/1,30 1,5% Yes (4)/No No/No No No 1/9 
7 F, 42 Volunteer Italy/Sierra 
Leone 
ND/Quinine iv 
(2 d) then po+ 
doxycycline 
H, J, D/None 4 9,30/4,30 14% Yes (2)/Yes 
(1) 
No/No No No 3/10 
8 M,52 Work Italy/Seneg
al 
ND/Quinine 
iv+ 
doxycycline 
H, J, S, A, He, 
,IC,RF/SA, 
ARDS 
5 3,00/1,45 20% Yes (5)/No Yes/Yes 
(14) 
Yes (4 
/5) 
Yes 
(21) 
21/43 
9 F,44 Tourism Italy/Ugand
a 
ND/Quinine+ 
doxycycline 
H,J, IC,A/S, 
ARDS, RF, Hy 
13 1,30/2,30 17% Yes (2)/Yes 
(1) 
Yes/Yes (7) Yes* 
(6+6) 
Yes 
(12) 
13/32 
10 M, 
41 
VFR Mali/Ivory 
Coast 
ND/Quinine 
iv+ 
doxycycline 
 J,RF/ARDS, SA (1)**3 1,16/1,20 1% Yes (3)/No No/Yes (3) No Yes 
(6)# 
6/24 
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11 M,28
§ 
Work Italy/ 
Cameroon 
ND/Quinine iv 
(2d) then 
DHAP+ 
doxycycline+ 
primaquine 
H, J/SA (1)**9 2,30/2,25 20% Yes (3)/No No/No No No 6/10 
12 F,44 VFR Senegal/Sen
egal 
ND/Quinine iv 
(3) then 
DHAp+ 
doxycycline 
S,H,J,SA/None 3*** (8) ND 15% Yes/No No/No No No 1/8 
VFR, visiting friends and relatives; WHO, World Health Organization; ICU, intensive care unit; RBC, red blood cell; FFP, fresh frozen plasma; CVVHDF, continuous venous-venous hemodiafiltration; H, 
hyperparasitaemia; J, jaundice; D, disseminated intravascular coagulation; S, shock; ARDS, adult respiratory distress syndrome; RF, renal failure; IC, impaired consciousness; A, acidosis; Hy, hypoglicemia; He, 
hemoglobinuria; SA, severe anemia; ND, not done; NA , not available. * Erythrocytapheresis; ** Both patients initially evaluated at ED of other hospital and discharged with a  diagnosis of “viral syndrome”*** This 
patient was initially hospitalized in an Internal Medicine ward with a diagnosis of pyelonephitis;; § This patient had concomitant P. vivax infection;# hemodialysis thrice weekly until discharge with serum creatinine 
6.6 mg/dL; IV, intravenous; po, orally; DHAp, dihydroartemisinin-piperaquine 
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Table 2- Laboratory findings and severity scores of 12 patients with severe P. falciparum malaria at the time of admission  to the ICU 
Patient 1 2 3 4* 5 6 7 8 9 10 11  12 Median 
Age 33 40 59 31 47 45 42 52 44 41 28 44 43 
Temperature 39 39 36 39 
 
38,3 40 39,3 40 38,2 39 38,5 39,5 40 39 
Mean arterial 
pressure mm Hg 
90 110 75 75 
 
78 50 80 90 60 55 115 70 90 78 
Ph (arterial)/lactate 7,44/0,7 7,46/4,8 7,40/1,3 7,33/2,7 
 
7,36/1,4 7,17/8,4 7,41/1,4 7,48/2,2 7,27/6,6 7,09/>1
5 
7,38/2,6 7,45/2,6 7,45/2,3 7,405/2,6 
HCO3- mmol/L 26,5 20,6 31 24,3 28,2 14,9 27,3 18,4 16,5 15,8 19 22,9 20,2 20,6 
Heart rate 85 100 84 110 110 140 110 94 150 125 110 118 100 110 
Respiratory rate 22 20 20 24 60 36 28 24 35 35 22 30 21 24 
Sodium, mmol/L 133 131 129 130 133 140 131 124 122 134 130 122 132 131 
K+, mmol/L 3,6 3,7 3,0 4 3,8 3,9 4,2 3,3 4,8 3,8 3,9 4 3,6 3,8 
Creatinine, mg/dL 0,93 1,23 0,53 1,19 1,08 4,24 1,48 1,09 5,41 7,27 8,89 2,31 2,06 1,48 
Glucose 114 85 83 67 53 74 83 106 100 49 96 131 132 85 
Hb, g/dL 14,5 9,6 11,1 9,2 8,6 8,4 6,9 10,4 8,4 7,1 8,4 6,5 7,0 8,4 
Ht, % 44,8 24,3 25,8 26.6 25 24 19,8 28,6 24 20,7 23,3 17,8 21,5 24 
Platelets/µL 13000 46,000 89,000 8,000 58,000 68,000 29,000 7,000 22,000 18,000 34,000 26,000 38,000 29,000 
WBCs/µL 5420 5070 5100 4860 6320 15,940 1700 4230 14.170 10950 6650 8100 3890 5420 
Bilirubin total 
mg/dL 
1,35 4,38 1,14 15,9 4,75 6,98 13,4 5,18 10,16 14,4 17,1 5,95 7,08 6,98 
D-dimer, ng/mL 520 >10.000 458 >10.000 1222 1271 9606 17781 >10000 7244 2850 6881 >10000 7244 
Albumin mg/dL NA 2600 NA 2900 - 1400 2200 1900 2400 1800 2200 2000 2800 2200 
Glasgow Coma 
Score 
15 11 15 15 8 3 13 13 10 10 15 14 15 13 
APACHE II 
-Predicted 
mortality 
7 
7,6% 
12 
14,6% 
10 
11,3% 
7 
7,6% 
17 
26,2% 
40 
91.1% 
14 
18.6% 
11 
12,9% 
31 
73.3% 
35 
83.1% 
38 
82 % 
17 
26.2% 
11 
15% 
14 
SAPS II 
- Predicted 
mortality 
15 
2 % 
31 
11,7% 
22 
4,7 % 
35 
16,7 % 
35 
16,7% 
90 
96.7 % 
41 
26,6 % 
41 
26,6% 
68 
81,3% 
64 
75,3% 
55 
57.5% 
50 
46,1% 
46 
37% 
41 
SOFA 
-Predicted 
5 
<10% 
9 
15-20% 
3 
< 10% 
12 
40-50% 
11 
40-50% 
19 
> 90% 
10 
40-50% 
8 
15-20% 
17 
>90% 
18 
> 90% 
12 
40-50% 
10 
40-50% 
11 
40-50% 
11 
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mortality 
MSA 
- Predicted 
mortality 
0 
2 % 
4 
40 % 
0 
2 % 
7 
90 % 
 
3 
40% 
9 
90 % 
0 
2 % 
0 
2% 
9 
90% 
5 
40% 
5 
40% 
1 
2% 
2 
2% 
3 
WHO > 5 No No No No No Yes No No Yes Yes No No No 3/12 
MSS 
-Predicted 
mortality 
1 
3.1% 
3 
7.5% 
0 
1.2% 
3 
7.5% 
9 
51.8% 
16 
96.1% 
5 
12% 
3 
7.5% 
12 
81.8% 
9 
51.8% 
7 
31.1% 
5 
12% 
6 
21.1% 
5 
CAM 1 2 0 1 3 4 0 2 4 3 1 1 1 1 
RCAM 1 2 1 1 4 3 2 2 3 3 1 2 1 2 
 
SAPS II, Simplified Acute Physiology Score II; SOFA, Sequential Organ Failure Assessment; MSA, Malaria Score in Adults; WHO, World Health Organization; MSS, 
malaria Severity Score; CAM, Coma Acidosis Malaria Score; RCAM, Respiratory Coma Acidosis Malaria; * Patient admitted twice in ICU 
 
 
 
 
 
 
 
 
 
 
 
